Valentis Cancer Care, Meerut

At Valentis Cancer Care (Meerut), the brief is unglamorous and exacting: take PET-CT from a test to a platform. Start with hardware that won’t become the bottleneck. The department runs a GE Discovery IQ 3-Ring PET/CT with the LightBurst PET detector for small-lesion clarity, and Q.Clear reconstruction for reproducible SUVs—useful when an oncologist is tracking real response, not radiology prose. The platform is tuned for high image quality at lower dose and faster scans, which matters when the day is oncology-heavy and the waiting room is full of fasting patients.

Diagnostics are built as a palette, not a single shade. FDG PET-CT remains the workhorse for staging, response assessment by SUV change, and sorting recurrence from post-treatment change across lung, lymphoma, colorectal, breast, and melanoma. The department treats glucose hypermetabolism as a quantitative signal, not a suggestion.

Prostate cancer pathways begin with PSMA PET-CT. The scan pushes value in two places: staging high-risk primary disease better than conventional imaging, and localising biochemical recurrence at low PSA—often below 0.5 ng/mL—so surgeons and radiation oncologists aren’t operating in the dark. It also doubles as the gatekeeper for Lu-177 PSMA therapy: no avidity, no therapy.

Neuroendocrine tumour work is anchored on DOTATATE PET-CT. The team uses SSTR-targeted imaging for localisation, whole-body staging, and theranostic planning. A Krenning-style positivity threshold isn’t an afterthought; it’s the criterion for PRRT eligibility and it shows up in the report, not just the MDT conversation.

Breast oncology adds a receptor map. FES PET-CT reads functional oestrogen-receptor status across the whole body, highlighting heterogeneity and explaining why one lesion ignores endocrine therapy while another responds. It is a biopsy-sparing decision aid when progression under ET demands a better compass.

Neurology isn’t left to inference. FDOPA PET-CT quantifies presynaptic dopaminergic integrity to separate Parkinson’s disease from essential tremor or drug-induced parkinsonism when the clinic is messy and the tremor won’t behave for an exam. The output is an objective pattern, not a hunch.

Bone disease is staged with NaF PET-CT when sensitivity matters. Active turnover lights up earlier than on planar scintigraphy, and integrated CT pins down lesions precisely enough to plan SBRT without guesswork.

Theranostics is designed as a closed loop. “See it” with a diagnostic tracer (e.g., Ga-68 PSMA) to confirm a valid molecular target, “treat it” with the matched therapeutic (e.g., Lu-177) on the same ligand—no loose ends between the two halves. Valentis runs full pathways today for prostate cancer (PSMA) and NETs (PRRT), not pilot projects.

Therapies are delivered with pre-defined gates. Lu-177 PSMA for mCRPC is reserved for progressive disease—typically post-abiraterone/enzalutamide and/or taxanes—with high PSMA-avidity documented on diagnostic PET. The protocol reads like a checklist because it is one.

PRRT with Lu-177 DOTATATE is offered to progressive, well-differentiated, SSTR-positive NETs after standard-dose somatostatin analogues have done their work. Eligibility depends on the scan, grade, and a paper trail of progression—not optimism.

For refractory solid tumours with an active stroma, FAPI therapy targets cancer-associated fibroblasts. It is particularly relevant where FDG is unhelpfully quiet but the tumour microenvironment isn’t; entry requires high FAPI-avidity on a diagnostic scan.

When biology escalates, so does the physics. Ac-225 targeted alpha therapy introduces high-LET, short-range damage for aggressive or Lu-177-refractory disease in prostate cancer and NETs—potent where beta has been outpaced.

The roadmap keeps moving. Access to emerging combinations—Ac-225 FAPI—and new theranostic pairs like Tb-161 PSMA extend options further, pairing beta emissions with low-energy Auger electrons for highly localised nuclear-level damage. The intent is to keep the centre current without experimental theatre.

Practice development sits underneath the technology. Referral information is written for decisions—prep, TATs, escalation paths—so scans arrive appropriate and on time. Reports are structured with quantitative anchors; MDTs close the loop. Operations, safety, and counselling are engineered to make therapy days uneventful. (More on the hospital’s PET-CT service: valentiscancerhospital.in/pet-ct-scan.php.)

Go To Top